Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec. 2.Read More
Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday.
At the end of June, an Independent Data Monitoring Committee stopped a Phase 3 trial of Galena’s NeuVax in early-stage breast cancer for futility.Read More